Evidence & regulatory context
- Mechanism
- Furanocoumarin (psoralen-type) natural product. ChEMBL holds no mechanism-of-action record, and max_phase is -1 (unknown clinical phase), so no clinical development stage can be asserted. No relevant ClinicalTrials.gov records: the Angelica dahurica keyword search returned only unrelated multi-herb TCM formula trials, which were excluded.
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- -1 / 4 (development scale, not regulatory approval)
- Synonyms
- Imperatorin; Ammidin; Marmelosin; 8-isoamylenoxypsoralen; NSC-402949; Pentosalen
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinC57BL/6 wild type; FXR knockout (B6.129X1(FVB)-Nr1h4tm1Gonz/J); liver-specific SIRT1 knockout (SIRT1 floxed crossed with Alb-cre)MaleOral gavage, suspended in 0.5 per cent CMC-NaIn vivo imperatorin dose not stated numerically, described…Prevention protocol: daily gavage for 5 days before acetaminophen challenge on…
Model: Acute liver injury induced by a single intraperitoneal overdose of acetaminophen at 300 mg/kg after overnight fasting, with separate lipopolysaccharide (25 mg/kg) and survival models
Imperatorin reduced acetaminophen- and lipopolysaccharide-induced mortality, lowered serum ALT and AST and reduced centrilobular necrosis, with the largest effect at the high dose. It restored FXR, SHP and BSEP expression, reduced pro-inflammatory cytokines and COX2, restored GSH/GSSG, Nrf2 and SOD…
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.